Structural Advantages:
- The CDR3 loop of a camelid VHH typically can be much longer allowing it to reach epitopes on target antigens inaccessible to conventional antibodies.
- VHH is its entirely hydrophilic framework, whereas a VH domain contains a hydrophobic side facing the VL domain (indicated in black). This may aid inclusion of vHHs into bi-specific antibodies and alternative formats.
Therapeutic Advantages:
- Their nanoscale dimensions enable deep penetration of tumors (15kDa, Diameter: 2.5nm)
- Certain nanobodies able to cross the blood brain barrier (BBB)
- High affinity and specificity for their target antigens
- Modularity, can be used as soluble fragment or fused t...Read more
Structural Advantages:
- The CDR3 loop of a camelid VHH typically can be much longer allowing it to reach epitopes on target antigens inaccessible to conventional antibodies.
- VHH is its entirely hydrophilic framework, whereas a VH domain contains a hydrophobic side facing the VL domain (indicated in black). This may aid inclusion of vHHs into bi-specific antibodies and alternative formats.
Therapeutic Advantages:
- Their nanoscale dimensions enable deep penetration of tumors (15kDa, Diameter: 2.5nm)
- Certain nanobodies able to cross the blood brain barrier (BBB)
- High affinity and specificity for their target antigens
- Modularity, can be used as soluble fragment or fused to FC or HSA or CAR-T receptors in bi- or multi-specific formats
Developability Advantages:
- High melting temperatures (60–80◦C, several weeks at 37◦C)
- Non-physiological pHs (3.0–9.0)
- Strong chemical denaturants (2–3 M guanidinium chloride, 6–8 M urea)
Manufacturing Advantages:
- Nanobodies are inexpensive to produce and can leverage existing manufacturing processes.
- Leverage standard Protein-A purification.
- Can be synthesized through microbial or mammalian expression systems